Abstract
As new agents are developed for osteoporosis prevention and intervention, the need for reliable animal models becomes more pressing. At the same time, the necessity of not focusing on bone mass as the sole efficacy parameter has become apparent. Before accepting any agent for clinical osteoporosis trials, FDA now requires that it has proven its efficacy in a small animal model and also in a larger animal model with known intracortical bone remodeling. This efficacy should be proven both concerning bone mass and bone biomechanical competence. In this paper, methods for testing bone quality in small and large animal models are presented, and the necessity of testing several skeletal sites: vertebrae, long bones, and femoral necks is discussed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
